394.00 +0.27 (0.07%)
After hours: 5:38PM EDT
Commodity Channel Index
|Bid||393.28 x 1100|
|Ask||395.79 x 1000|
|Day's Range||392.41 - 407.35|
|52 Week Range||208.25 - 412.70|
|Beta (5Y Monthly)||0.91|
|PE Ratio (TTM)||20.97|
|Earnings Date||Aug 05, 2020|
|Forward Dividend & Yield||2.50 (0.62%)|
|Ex-Dividend Date||Jun 29, 2020|
|1y Target Est||427.86|
Humana's (HUM) arm Partners in Primary Care to unveil 20 new medical care centers with focus to serve seniors. There are further plans to extend reach in Houston with 10 more centers.
Humana Inc. (NYSE: HUM) announced today that Brian A. Kane, Chief Financial Officer, will make a presentation to investors at the Goldman Sachs Healthcare Conference on Thursday, June 11, 2020, at 8:00 a.m. Eastern time.
Humana's (HUM) new agreement intends to efficiently serve Medicaid members of Kentucky, where it already boasts of a strong base.
Humana Awarded New Contract to Continue Serving Medicaid Managed Care Residents in Home State of Kentucky
Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Humana Inc. (NYSE: HUM) announced today that Brian A. Kane, Chief Financial Officer, will make a presentation to investors at the Jefferies Healthcare Conference on Thursday, June 4, 2020, at 10:00 a.m. Eastern time.
In this article we will check out the progression of hedge fund sentiment towards Humana Inc (NYSE:HUM) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 […]
Louisville Nonprofits Receive $2.2 Million through Humana Foundation’s Community Partners Program
The coronavirus pandemic has helped digital health surge like never before. With virtual visits increasing on a daily basis, we have five stocks that are set to gain.
For investors, increase in profitability and industry-beating performance can be essential considerations in an...
We're starting to see a little light at the end of the coronavirus tunnel. State economies are slowly reopening and the market has recovered mightily from March's historic losses.It's true that as we go forward, the lingering effects of stay-at-home orders, a spiking unemployment rate and desperate stimulus measures make for record uncertainty. But we are also starting to understand which types of stocks ought to benefit when the crisis is resolved. * 7 Excellent Penny Stocks Ready to Roar Here are 7 of the top-rated stocks to buy for a post-crisis rally:InvestorPlace - Stock Market News, Stock Advice & Trading Tips * Co-Diagnostics (NASDAQ:CODX) (A) * Humana (NYSE:HUM) (A) * iBio (NYSE:IBIO) (A) * Moderna (NASDAQ:MRNA) (A) * Alibaba (NYSE:BABA) (B) * Square (NYSE:SQ) (B)Four of these stocks hold "A" ratings on my Portfolio Grader, while two hold "B" ratings. All make smart buys here. Co-Diagnostics (CODX)Source: Shutterstock If you're looking for a post-crisis bump, no list of stocks to buy would be complete without somehow representing the healthcare sector.Enterprising investors should consider CODX as we transition to a new era. Regardless of one's personal thoughts on how to best handle the days ahead, one thing is certain: testing will be absolutely central to any return to normal.For reasons both scientific and psychological, the widespread demand for Covid-19 testing is one of the only givens in these uncertain times. CODX, a previously little-known diagnostics company, was founded in 2013 with a focus on the sale of reagents needed for coronavirus tests.Although Co-Diagnostics shares fell after the most recent earnings report, the roughly $600 million CODX, which has been increasingly watched by investors, makes test kits that should be an important part of re-opening the U.S. economy in 2020, even if accuracy doesn't hit the 100% level the company has claimed.Rating: (A) Humana (HUM)Health insurer Humana has been absolutely shining in 2020, despite the novel coronavirus wreaking havoc across the economy. Shares are up more than 60% year-to-date, and the Louisville, Kentucky-based health plan giant is coming off a killer first-quarter earnings report.In sharp contrast to rivals like Anthem (NYSE:ANTM), which recently withdrew its full-year 2020 guidance, Humana posted blowout Q1 earnings. The company reported revenue of $18.93 billion against analyst expectations for $18.38 billion. On the earnings per share (EPS) side, HUM stock reported EPS of $5.40 versus the $4.84 consensus expectation.The top- and bottom-line beats were also accompanied by an optimistic outlook for the rest of 2020; Humana guided for EPS between $18.25 and $18.75, for a median of $18.50, above the $18.44 per share consensus expectations. * 7 Excellent Penny Stocks Ready to Roar Rating: (A) iBio (IBIO)Source: Shutterstock If there is a coronavirus vaccine, the small-cap biotech iBio could end up being a major beneficiary. Although certainly more speculative in nature than a stock like Humana, the roughly $100 million IBIO could see shares continue to surge when a vaccine is rolled out. Shares of IBIO have already jumped about 500% in 2020, but there's still upside to be had.That's because the company is boasting capacity of about 500 million doses should their much-anticipated vaccine come to fruition. Few investors take the time to think through not just the companies that are researching the vaccine itself, but those that will be necessary to manufacture and distribute the vaccine.The New York, New York-based IBIO has a Texas manufacturing facility that should be able to make 500 million doses of a vaccine annually -- the sort of capacity necessary when a vaccine is invented. In theory, this should be enough capacity to supply and vaccinate not just all of the U.S. (328 million people), but also the entire populations of Mexico (126 million) and Canada (38 million).Rating: (A) Moderna (MRNA)Source: Shutterstock The source of some major market-moving news in recent days, Cambridge, Massachusetts-based Moderna is a clinical biotechnology company. As its ticker indicates, it uses messenger RNA (mRNA) in vaccines and other treatments for infectious diseases.Promising early results in a coronavirus vaccine trial in human patients vaulted MRNA shares to all-time highs and helped send the entire market higher to boot. The phase one trial included 45 participants and saw the production of antibodies in 100% of them, a very encouraging sign as the entire world races to come up with an efficacious vaccine that can be manufactured and distributed at scale. * 7 Excellent Penny Stocks Ready to Roar Rating: (A) Alibaba (BABA)Source: BigTunaOnline / Shutterstock.com Who would've thought that one of the largest companies in China would be listed as one of the best stocks to buy in a post-crisis rally? Although Wuhan, China, was the early epicenter of the global pandemic, China's swift moves to lockdown its sprawling country and rapidly rollout contact tracing mitigated the harm of the pandemic.And BABA stock, for its part, has held up quite well. Like its closest American counterpart Amazon.com (NASDAQ:AMZN), Alibaba has actually leveraged it large market share and impressive logistics network to cement its status as a powerhouse in e-commerce, which has gotten an obvious boost as mandated lockdowns dried up demand across Chinese brick-and-mortar retailers.Trading at 22 times earnings and with a market cap above $500 billion, BABA offers a unique combination of size, growth and affordability. On the growth side, it saw revenue jump 38% last quarter and earnings per share increase 55%.Rating: (B) Square (SQ)Source: Jonathan Weiss / Shutterstock.com Last but not least, payments company Square rounds out our list of the top-rated stocks to buy when the crisis resolves.The provider of point-of-sale solutions for businesses has been a growth stock for some time now, and its solutions include contactless payments -- something that should doubtlessly gain share in the months and years ahead as the pandemic changes consumer behavior.Revenue has grown at a 41% clip over the last five years, and analysts expect profits to be the next metric to really take off in coming years, with consensus expectations calling for a 31% compound annual growth rate in earnings per share over the next five years. * 7 Excellent Penny Stocks Ready to Roar Rating: (B)Louis Navellier had an unconventional start, as a grad student who accidentally built a market-beating stock system -- with returns rivaling even Warren Buffett. In his latest feat, Louis discovered the "Master Key" to profiting from the biggest tech revolution of this (or any) generation. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * Top Stock Picker Reveals His Next 1,000% Winner * America's Richest ZIP Code Holds Shocking Secret * 1 Under-the-Radar 5G Stock to Buy Now * The 1 Stock All Retirees Must Own The post 6 Top-Rated Stocks for a Post-Coronavirus-Crisis Bump appeared first on InvestorPlace.
Humana and Healthmap Solutions Sign Agreement for Kidney Disease Care Coordination Services in Florida
Humana's (HUM) solid Medicare business and inorganic growth story will likely boost its revenues, which in turn, might bump up its share price.
According to Greg Fann and Dave Dillon, fellows of the Society of Actuaries who work directly with insurers to set health insurance premium rates, costs will be up “in the 4-6% range for the individual and small group market.” Yahoo Finance’s Ethan Wolff-Mann joins Seana Smith to discuss.
Humana’s annual report on employee well-being illustrates the company’s culture and highlights resiliency.